Correlation between Expression of C-erbB2 Oncoprotein and the Prognostic Factors in Endometrial Cancer.
- Author:
Young Tae KIM
1
;
Hae Jeong YOON
;
Dong Hyun KIM
;
Hak Cheon LEE
;
Sei Kwang KIM
;
Jae Wook KIM
Author Information
1. Department of Obsterics and Gynecology, Yonsei University Colloge of Medicine, Seoul, korea.
- Publication Type:Original Article
- Keywords:
C-erbB-2 oncoprotein;
Endometrial cancer;
Prognostic factors
- MeSH:
Adenocarcinoma;
Endometrial Neoplasms*;
Estrogens;
Female;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Oncogenes;
Phenotype;
Prognosis;
Protein-Tyrosine Kinases;
Uterus
- From:Korean Journal of Obstetrics and Gynecology
1997;40(4):847-855
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The c-erbB-2 oncogene encodes a 185,00 dalton transmembrane glycoportein with tyrosine kinase activity, and the aberrant overexpression of which has been implicated in the indution of a malignat phenotype. Overexpression of the c-erbB-2 has been found in many human adenocarcinomas, especially mammarian and ovarian carcinomas, and that is associated with poor prognosis. We used an enzyme-linked immunosorbent assay(ELISA) to explore the relationship between c-erbB-2 oncoprotein and prognostic factors of endmetrial cancer and analyzed the tissued form the 24patients with endometiral cancer and 10 control cases. patinens with endometrial cancer were found to bave 20% of c-erbB-2 oncoprotein overexpression rate and signficiantly higher c-erbB-2 median oncoprotein expression than conterolC-erbB-2 oncoprotein overexpression showed no statistically significant association with known prognostic factors including stage, grade, histologic cell type, myometrial invasion and lymph node metastases, although the c-erbB-2 oncoprotein overexpression rate was increased by stage, and was higher in lymph node metastatic group than in confined to the uterus goup. High c-erbB-2 oncoprotein overexpression was correlated with absence of estrogen receptor (Rs=-0.46, p=0.047) and progestreone receptor (Rs=-0.57, p=0.045), further studies are needed to determine the significance of the c-erbB-2 everexpression in endometrial cancer.
